{
    "root": "35b5afa9-33f7-60bc-e063-6394a90a71db",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Eszopiclone",
    "value": "20250522",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "ESZOPICLONE",
            "code": "UZX80K71OE"
        }
    ],
    "indications": "eszopiclone tablets indicated treatment insomnia . controlled outpatient sleep laboratory , eszopiclone tablets administered bedtime decreased sleep latency improved sleep maintenance . trials performed support efficacy 6 months duration . final formal assessments sleep latency maintenance performed 4 weeks 6-week study ( adults ) , end 2-week ( elderly ) end 6-month study ( adults ) .",
    "contraindications": "lowest effective dose patient .",
    "warningsAndPrecautions": "eszopiclone tablets , usp , 3 mg round , dark blue , film-coated , identified debossed markings ‘ 384 ’ one side , ‘ g ’ side supplied : ndc 76420-354-30 bottle 30 tablets ( relabeled ndc 68462-384-30 ) ndc 76420-354-60 bottle 60 tablets ( repackaged ndc 68462-384-xx ) ndc 76420-354-90 bottle 90 tablets ( repackaged ndc 68462-384-xx ) ndc 76420-354-01 bottle 100 tablets ( relabeled ndc 68462-384-01 ) ndc 76420-354-10 bottle 1000 tablets ( relabeled ndc 68462-384-10 ) eszopiclone tablets , usp , 2 mg round , white off-white , film-coated , identified debossed markings ‘ 383 ’ one side , ‘ g ’ side supplied : ndc 76420-353-30 bottle 30 tablets ( repackaged ndc 68462-383-xx ) ndc 76420-353-60 bottle 60 tablets ( repackaged ndc 68462-383-xx ) ndc 76420-353-90 bottle 90 tablets ( repackaged ndc 68462-383-xx ) ndc 76420-353-01 bottle 100 tablets ( relabeled ndc 68462-383-01 ) ndc 76420-353-10 bottle 1000 tablets ( relabeled ndc 68462-383-10 ) eszopiclone tablets , usp , 1 mg round , light blue , film-coated , identified debossed markings ‘ 382 ’ one side , ‘ g ’ side supplied : ndc 76420-352-30 bottle 30 tablets ( relabeled ndc 68462-382-30 ) ndc 76420-352-60 bottle 60 tablets ( repackaged ndc 68462-382-xx ) ndc 76420-352-90 bottle 90 tablets ( repackaged ndc 68462-382-xx ) ndc 76420-352-01 bottle 100 tablets ( relabeled ndc 68462-382-01 ) ndc 76420-352-10 bottle 1000 tablets ( relabeled ndc 68462-382-10 ) store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°f 30°c ( 59°f 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "eszopiclone tablets contraindicated patients experienced complex sleep behaviors taking eszopiclone tablets [ ( 5.1 ) ] . eszopiclone tablets contraindicated patients known hypersensitivity eszopiclone . hypersensitivity include anaphylaxis angioedema [ ( 5.3 ) ] .",
    "indications_original": "Eszopiclone tablets are indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance.\n                  The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only).",
    "contraindications_original": "Use the lowest effective dose for the patient.",
    "warningsAndPrecautions_original": "Eszopiclone Tablets, USP, 3 mg are round, dark blue, film-coated, and identified with debossed markings of ‘384’ on one side, and ‘G’ on the other side and are supplied as:\n                         NDC 76420-354-30 bottle of 30 tablets (relabeled from NDC 68462-384-30)\n                         NDC 76420-354-60 bottle of 60 tablets (repackaged from NDC 68462-384-XX)\n                         NDC 76420-354-90 bottle of 90 tablets (repackaged from NDC 68462-384-XX)\n                         NDC 76420-354-01 bottle of 100 tablets (relabeled from NDC 68462-384-01)\n                         NDC 76420-354-10 bottle of 1000 tablets (relabeled from NDC 68462-384-10)\n                  Eszopiclone Tablets, USP, 2 mg are round, white to off-white, film-coated, and identified with debossed markings of ‘383’ on one side, and ‘G’ on the other side and are supplied as:\n                         NDC 76420-353-30 bottle of 30 tablets (repackaged from NDC 68462-383-XX)\n                         NDC 76420-353-60 bottle of 60 tablets (repackaged from NDC 68462-383-XX)\n                         NDC 76420-353-90 bottle of 90 tablets (repackaged from NDC 68462-383-XX)\n                         NDC 76420-353-01 bottle of 100 tablets (relabeled from NDC 68462-383-01)\n                         NDC 76420-353-10 bottle of 1000 tablets (relabeled from NDC 68462-383-10)\n                  Eszopiclone Tablets, USP, 1 mg are round, light blue, film-coated, and identified with debossed markings of ‘382’ on one side, and ‘G’ on the other side and are supplied as:\n                         NDC 76420-352-30 bottle of 30 tablets (relabeled from NDC 68462-382-30)\n                         NDC 76420-352-60 bottle of 60 tablets (repackaged from NDC 68462-382-XX)\n                         NDC 76420-352-90 bottle of 90 tablets (repackaged from NDC 68462-382-XX)\n                         NDC 76420-352-01 bottle of 100 tablets (relabeled from NDC 68462-382-01)\n                         NDC 76420-352-10 bottle of 1000 tablets (relabeled from NDC 68462-382-10)\n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°F to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Eszopiclone tablets are contraindicated in patients who have experienced complex sleep behaviors after taking eszopiclone tablets\n  \n    [see Warnings and Precautions (\n                           \n                              5.1)]\n  \n    .\n \n   \n                     \n                     Eszopiclone tablets are contraindicated in patients with known hypersensitivity to eszopiclone. Hypersensitivity reactions include anaphylaxis and angioedema\n  \n   [see Warnings and Precautions (\n   \n    5.3)]."
}